• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Paychex Reports Downbeat Sales, Joins BlackBerry And Other Big Stocks Moving Lower On Thursday

    12/21/23 11:02:00 AM ET
    $BB
    $ISPR
    $MOR
    $MULN
    Computer Software: Prepackaged Software
    Technology
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $BB alert in real time by email

    U.S. stocks traded higher, with the Dow Jones index gaining around 200 points on Thursday.

    Shares of Paychex, Inc. (NASDAQ:PAYX) moved lower during Thursday’s session after the company reported worse-than-expected second-quarter revenue results and issued FY24 guidance.

    Paychex reported second-quarter FY24 sales growth of 6% year-on-year to $1.26 billion, slightly missing the analyst consensus estimate of $1.27 billion. Adjusted EPS of $1.08 beat the analyst consensus estimate of $1.07, according to Benzinga Pro.

    Paychex shares fell 5.4% to $120.96 on Thursday.

    Here are some other big stocks recording losses in today’s session.

    Jin Medical International Ltd. (NASDAQ:ZJYL) shares fell 14.3% to $71.62. On Dec 18, Jin Medical International received Nasdaq letter notifying that the company failed to give detailed plan to support decision for further time for compliance.

    Ispire Technology Inc. (NASDAQ:ISPR) declined 14.1% to $11.78.

    BlackBerry Limited (NYSE:BB) declined 12.3% to $3.5950 following the release of third-quarter results.

    Cassava Sciences, Inc. (NASDAQ:SAVA) shares fell 10.7% to $24.78.

    MorphoSys AG (NASDAQ:MOR) fell 7.9% to $8.61.

    Diversified Energy Company PLC (NYSE:DEC) dipped 7.6% to $14.04.

    Zai Lab Limited (NASDAQ:ZLAB) fell 6.6% to $26.93.

    Nanobiotix S.A. (NASDAQ:NBTX) declined 6.4% to $6.21.

    Value Line, Inc. (NASDAQ:VALU) fell 6% to $45.80.

    Mullen Automotive, Inc. (NASDAQ:MULN) fell 5.5% to $7.56. Mullen announced that it delivered 38 additional Class 3 vehicles to Randy Marion Automotive Group and sent the company an invoice for $2.5 million.

    Warner Bros. Discovery, Inc. (NYSE:WBD) fell 4.8% to $11.10. David Zaslav, CEO of Warner Bros. Discovery, and Bob Bakish, CEO of Paramount Global, met on Tuesday and spoke for several hours about a potential merger.

    Now Read This: Dow Jumps 250 Points; US Weekly Jobless Claims Edge Higher

    Get the next $BB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BB
    $ISPR
    $MOR
    $MULN

    CompanyDatePrice TargetRatingAnalyst
    Paychex Inc.
    $PAYX
    3/19/2026Neutral
    Guggenheim
    Paychex Inc.
    $PAYX
    3/13/2026$121.00 → $103.00Market Perform
    BMO Capital Markets
    Warner Bros. Discovery Inc.
    $WBD
    3/9/2026$31.00Equal Weight
    Wells Fargo
    Warner Bros. Discovery Inc.
    $WBD
    2/27/2026Buy → Hold
    The Benchmark Company
    Warner Bros. Discovery Inc.
    $WBD
    2/27/2026Outperform → Underperform
    Raymond James
    Warner Bros. Discovery Inc.
    $WBD
    2/27/2026$31.25Buy → Neutral
    Arete
    Warner Bros. Discovery Inc.
    $WBD
    2/17/2026$31.00Buy → Neutral
    Rothschild & Co Redburn
    Nanobiotix S.A.
    $NBTX
    2/6/2026Buy
    TD Cowen
    More analyst ratings

    $BB
    $ISPR
    $MOR
    $MULN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Co-Chief Executive Officer Wang Michael Xue bought $11,959 worth of shares (5,000 units at $2.39), increasing direct ownership by 1% to 466,882 units (SEC Form 4)

    4 - Ispire Technology Inc. (0001948455) (Issuer)

    3/2/26 4:58:37 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Co-Chief Executive Officer Wang Michael Xue bought $18,529 worth of shares (8,000 units at $2.32), increasing direct ownership by 2% to 461,882 units (SEC Form 4)

    4 - Ispire Technology Inc. (0001948455) (Issuer)

    2/26/26 4:27:49 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    Director Bonadio Tom bought $98,498 worth of shares (1,000 units at $98.50), increasing direct ownership by 5% to 21,504 units (SEC Form 4)

    4 - PAYCHEX INC (0000723531) (Issuer)

    2/5/26 4:00:03 PM ET
    $PAYX
    Diversified Commercial Services
    Industrials

    $BB
    $ISPR
    $MOR
    $MULN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Paychex

    Guggenheim initiated coverage of Paychex with a rating of Neutral

    3/19/26 8:27:01 AM ET
    $PAYX
    Diversified Commercial Services
    Industrials

    BMO Capital Markets reiterated coverage on Paychex with a new price target

    BMO Capital Markets reiterated coverage of Paychex with a rating of Market Perform and set a new price target of $103.00 from $121.00 previously

    3/13/26 8:23:59 AM ET
    $PAYX
    Diversified Commercial Services
    Industrials

    Wells Fargo resumed coverage on Warner Bros. Discovery with a new price target

    Wells Fargo resumed coverage of Warner Bros. Discovery with a rating of Equal Weight and set a new price target of $31.00

    3/9/26 9:13:19 AM ET
    $WBD
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    $BB
    $ISPR
    $MOR
    $MULN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NANOBIOTIX Announces Presentation of First Data from a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer

    Data presented by Johnson & Johnson at the 2026 European Lung Cancer Conference PARIS and CAMBRIDGE, Mass., March 30, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (NASDAQ:NBTX), a late-clinical stage biotechnology company pioneering nanotherapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced the presentation of first data from the CONVERGE study, a Johnson & Johnson-sponsored randomized Phase 2 clinical trial evaluating potential first-in-class Nanoradioenhancer JNJ-1900 (NBTXR3) for patients with stage 3 inoperable non-small cell lung cancer, at the 2026 European Lung Cancer Conference. POSTER #297P: Novel Intratumoral Radioen

    3/30/26 2:30:00 AM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NANOBIOTIX to Announce Fourth Quarter and Full Year 2025 Operational and Financial Update on March 31st, 2026

    PARIS and CAMBRIDGE, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ:NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that it will report its financial results for the fourth quarter and full year ended December 31, 2025, on Tuesday, March 31st, 2026, after the close of the U.S. market. This release will be followed by a conference call and webcast on Wednesday, April 1st, 2026, at 8:00 AM EDT / 2:00 PM CEST, prior to the open of the U.S. market. During the call, Laurent Levy, chief executive office

    3/26/26 4:15:00 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Warner Bros. Discovery Sets Shareholder Meeting Date of April 23, 2026 to Approve Transaction with Paramount Skydance

    WBD Shareholders Have Opportunity to Vote on All-Cash Transaction with Clear Path to CloseBoard Unanimously Recommends Shareholders Vote FOR Paramount MergerNEW YORK, March 26, 2026 /PRNewswire/ -- Warner Bros. Discovery, Inc. ("WBD" or "Warner Bros. Discovery") (NASDAQ:WBD) today announced that it will hold the Special Meeting of Shareholders (the "Special Meeting") to vote on the merger with Paramount Skydance Corporation ("Paramount") (NASDAQ:PSKY) on April 23, 2026 at 10:00 a.m. Eastern Time. It also announced that it has commenced mailing of the definitive proxy statement to shareholders in connection with the Special Meeting. WBD shareholders of record as of 5:00 p.m. Eastern Time on M

    3/26/26 9:10:00 AM ET
    $PSKY
    $WBD
    Broadcasting
    Industrials
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    $BB
    $ISPR
    $MOR
    $MULN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Gaynor Richard

    4 - Zai Lab Ltd (0001704292) (Issuer)

    3/19/26 4:05:38 PM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Fargis John

    4 - Ispire Technology Inc. (0001948455) (Issuer)

    3/19/26 4:02:32 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 4 filed by Cox Brent

    4 - Ispire Technology Inc. (0001948455) (Issuer)

    3/19/26 4:02:12 PM ET
    $ISPR
    Medicinal Chemicals and Botanical Products
    Health Care

    $BB
    $ISPR
    $MOR
    $MULN
    SEC Filings

    View All

    SEC Form 6-K filed by Nanobiotix S.A.

    6-K - Nanobiotix S.A. (0001760854) (Filer)

    3/30/26 6:00:09 AM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Warner Bros. Discovery Inc.

    SCHEDULE 13G/A - Warner Bros. Discovery, Inc. (0001437107) (Subject)

    3/27/26 2:13:20 PM ET
    $WBD
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Amendment: SEC Form SCHEDULE 13G/A filed by Paychex Inc.

    SCHEDULE 13G/A - PAYCHEX INC (0000723531) (Subject)

    3/27/26 11:18:11 AM ET
    $PAYX
    Diversified Commercial Services
    Industrials

    $BB
    $ISPR
    $MOR
    $MULN
    Leadership Updates

    Live Leadership Updates

    View All

    WM Technology, Inc. Appoints Harry DeMott and Brent Cox to Board of Directors and Announces Executive Employment Arrangement with CFO Susan Echard

    WM Technology, Inc. ("WM Technology" or the "Company") (NASDAQ:MAPS), a leading marketplace and technology solutions provider to the cannabis industry, today announced the appointment of Harry DeMott and Brent Cox to the Company's Board of Directors, effective February 1, 2026. The Company also announced that Susan Echard will continue to serve as Chief Financial Officer, transitioning from a contracted arrangement to employment with the Company, effective January 30, 2026. "We are pleased to welcome Harry and Brent to WM Technology's Board of Directors. They each bring a combination of cannabis industry perspective, technology fluency, and disciplined capital markets experience," said Do

    2/3/26 5:45:00 PM ET
    $ISPR
    $MAPS
    Medicinal Chemicals and Botanical Products
    Health Care
    Computer Software: Prepackaged Software
    Technology

    Paychex Expands Board of Directors, Appoints New Member

    Experienced executive, J. Michael Hansen, appointed to Paychex Board of Directors Paychex, Inc. (NASDAQ:PAYX), an industry-leading human capital management (HCM) company, announced today that the company's Board of Directors has voted to expand to 11 members from 10 members. The Board has also appointed J. Michael Hansen to fill the new position as an independent director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260119850035/en/ Mr. Hansen brings deep financial expertise, having served as Executive Vice President & Chief Financial Officer (CFO) of Cintas Corporation (NASDAQ:CTAS) for more than 10 years. Upon his retirem

    1/20/26 8:30:00 AM ET
    $CTAS
    $PAYX
    Garments and Clothing
    Industrials
    Diversified Commercial Services

    VALUE LINE, INC. DECLARES A QUARTERLY CASH DIVIDEND OF $0.325 PER COMMON SHARE AND APPOINTS NEW BOARD MEMBER

    NEW YORK, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Value Line, Inc. (NASDAQ: VALU) announced today that its Board of Directors declared on January 16, 2026 a quarterly cash dividend of $0.325 per common share, payable on February 10, 2026, to stockholders of record on January 26, 2026. The Company has 9,387,957 shares of common stock outstanding as of January 16, 2026. The Company also announced that the Board has appointed Dr. Alexander J. Swistel to its Board of Directors and as a member of the Board's Audit Committee.         Value Line is a leading provider of investment research. The Value Line Investment Survey is one of the most widely used sources of independent equity research.        

    1/16/26 3:20:00 PM ET
    $VALU
    Investment Managers
    Finance

    $BB
    $ISPR
    $MOR
    $MULN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Zai Lab Limited

    SC 13G - Zai Lab Ltd (0001704292) (Subject)

    11/14/24 11:11:39 AM ET
    $ZLAB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Paychex Inc.

    SC 13G/A - PAYCHEX INC (0000723531) (Subject)

    11/13/24 10:27:58 AM ET
    $PAYX
    Diversified Commercial Services
    Industrials

    Amendment: SEC Form SC 13G/A filed by BlackBerry Limited

    SC 13G/A - BLACKBERRY Ltd (0001070235) (Subject)

    11/12/24 4:01:20 PM ET
    $BB
    Computer Software: Prepackaged Software
    Technology

    $BB
    $ISPR
    $MOR
    $MULN
    Financials

    Live finance-specific insights

    View All

    NANOBIOTIX to Announce Fourth Quarter and Full Year 2025 Operational and Financial Update on March 31st, 2026

    PARIS and CAMBRIDGE, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ:NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that it will report its financial results for the fourth quarter and full year ended December 31, 2025, on Tuesday, March 31st, 2026, after the close of the U.S. market. This release will be followed by a conference call and webcast on Wednesday, April 1st, 2026, at 8:00 AM EDT / 2:00 PM CEST, prior to the open of the U.S. market. During the call, Laurent Levy, chief executive office

    3/26/26 4:15:00 PM ET
    $NBTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Paychex Reports Third Quarter Results

    Achieved Strong Double-Digit Revenue and Operating Income Growth Accelerated Organic Revenue Growth Returned Over $1.5 Billion to Shareholders Fiscal Year to Date Paychex, Inc. (NASDAQ:PAYX) (the "Company," "Paychex," "we," "our," or "us"), an industry-leading human capital management ("HCM") company, today reported results for the fiscal quarter ended February 28, 2026 (the "third quarter") of the fiscal year ending May 31, 2026 ("fiscal 2026"). Results compared with the same period last year were as follows:     For the three months ended             For the nine months ended          

    3/25/26 8:30:00 AM ET
    $PAYX
    Diversified Commercial Services
    Industrials

    VALUE LINE, INC. ANNOUNCES THIRD QUARTER EARNINGS

    NEW YORK, March 16, 2026 (GLOBE NEWSWIRE) -- Value Line, Inc., (NASDAQ: VALU) reported financial results for the third fiscal quarter ended January 31, 2026. During the nine months ended January 31, 2026, the Company's net income of $18,052,000, or $1.92 per share, was 7.9% above net income of $16,735,000, or $1.78 per share, for the nine months ended January 31, 2025.  During the nine months ended January 31, 2026, the Company's total investment gains of $5,379,000 was 51.2% above total investment gains in the prior fiscal year.  Retained earnings at January 31, 2026, were $122,285,000, an increase of 7.8% compared to retained earnings at April 30, 2025.  Shareholders' equity reached $10

    3/16/26 6:10:00 PM ET
    $VALU
    Investment Managers
    Finance